InSphero, ETH, and Children’s Hospital develop new microfluidics platform
Together with ETH Zürich and the University Children’s Hospital Zürich, InSphero developed and characterized a gravity-driven microfluidic platform that enables continuous co-culture of suspension cells with 3D microtissues under physiologically relevant flow. No pumps, no tubing, just smart design.
The study presents the design and characterization of the system, the scientific foundation of our Akura™ Immune Flow Organ-on-Chip Platform, demonstrating how controlled tilting enables gentle, pump-free perfusion that keeps cells in suspension and eliminates sedimentation artifacts. A proof-of-concept study with immune and tumor cells highlights the platform’s potential for immune-oncology research.
While this is just one example, the platform supports a broad range of applications involving circulating cells: from immune-oncology and inflammation to metastasis research.
👏 A big congratulations to our collaborators and the InSphero team for their dedication and ingenuity. We’re excited to see how this technology will be adopted and applied by scientists and innovators worldwide!
👉 Explore the full publication and learn more about the Akura™ Immune Flow Organ-on-Chip Platform via the link below.